$GKOS stock has now risen 2% today, according to our price data from Polygon. There has been approximately $19,437,150 of trading volume.
Here is what we see in our data on $GKOS (you can track the company live on Quiver's $GKOS stock page):$GKOS Insider Trading Activity
$GKOS insiders have traded $GKOS stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $GKOS stock by insiders over the last 6 months:
- TOMAS NAVRATIL (CHIEF DEVELOPMENT OFFICER) has made 0 purchases and 2 sales selling 5,142 shares for an estimated $453,620.
- ALEX R. THURMAN (SVP & CHIEF FINANCIAL OFFICER) has made 0 purchases and 3 sales selling 1,520 shares for an estimated $162,398.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$GKOS Hedge Fund Activity
We have seen 183 institutional investors add shares of $GKOS stock to their portfolio, and 196 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,039,514 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $107,371,401
- WELLINGTON MANAGEMENT GROUP LLP added 953,614 shares (+41.6%) to their portfolio in Q2 2025, for an estimated $98,498,790
- 1832 ASSET MANAGEMENT L.P. removed 723,300 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $71,187,186
- POINT72 ASSET MANAGEMENT, L.P. added 719,262 shares (+inf%) to their portfolio in Q2 2025, for an estimated $74,292,571
- PRIMECAP MANAGEMENT CO/CA/ added 609,523 shares (+50.0%) to their portfolio in Q2 2025, for an estimated $62,957,630
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 473,153 shares (-48.6%) from their portfolio in Q2 2025, for an estimated $48,871,973
- INVESCO LTD. removed 455,024 shares (-31.3%) from their portfolio in Q2 2025, for an estimated $46,999,428
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$GKOS Government Contracts
We have seen $266,562 of award payments to $GKOS over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PROS IMPLANT: $42,621
- PROS IMPLANT: $42,621
- PROSTHETICS. SURGICAL IMPLANT: $21,340
- LEFT EYE IDOSE ISENT: $21,340
- RIGHT EYE IDOSE ISENT: $21,340
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
$GKOS Analyst Ratings
Wall Street analysts have issued reports on $GKOS in the last several months. We have seen 8 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 09/10/2025
- UBS issued a "Buy" rating on 07/31/2025
- Morgan Stanley issued a "Underweight" rating on 05/06/2025
- Stephens & Co. issued a "Overweight" rating on 05/02/2025
- Stifel issued a "Buy" rating on 05/01/2025
- Truist Securities issued a "Buy" rating on 05/01/2025
- Needham issued a "Buy" rating on 05/01/2025
To track analyst ratings and price targets for $GKOS, check out Quiver Quantitative's $GKOS forecast page.
$GKOS Price Targets
Multiple analysts have issued price targets for $GKOS recently. We have seen 10 analysts offer price targets for $GKOS in the last 6 months, with a median target of $116.5.
Here are some recent targets:
- Ryan Zimmerman from BTIG set a target price of $118.0 on 09/10/2025
- Larry Biegelsen from Wells Fargo set a target price of $92.0 on 07/31/2025
- Danielle Antalffy from UBS set a target price of $134.0 on 07/31/2025
- Patrick Wood from Morgan Stanley set a target price of $72.0 on 05/06/2025
- Mason Carrico from Stephens & Co. set a target price of $115.0 on 05/02/2025
- Thomas Stephan from Stifel set a target price of $115.0 on 05/01/2025
- Richard Newitter from Truist Securities set a target price of $135.0 on 05/01/2025
You can track data on $GKOS on Quiver Quantitative.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
